everyone. afternoon, third us for highlights join thank you as and recent quarter business we provide discuss Good taking Josh. once time XXXX the financial you, results. And Thank of our to today again an overview
most LaFrance, by our call Sims, progress the me recent Norman to and Officer. I will is call Joining us company corporate for remember. to Medical Andrew And the a today Andrew Chief financials. The be Dr. ever our I'll for quarter Officer, begin reviewing clinical single review progress Financial Chief the turning can in the that joining before LaFrance call Dr. Q&A. our over perhaps our made
had equals our in tumors catheters radiation eight one from mean single for delivery treatment exposure. of intracranial for volume. radiation presented absorbed a RNL Gy patients XX that mean patients Phase was XXX.X delivered the XX.X X.X XX and that mCi stratified September dosimetry the mean were with Each Phase those receiving overall group. essentially safe had none than XX mean company's drug X.X those equal patients and of for with lead planning the further of that was systemic Patients four CCs X XX.X the XXX to XX and was sub distribution. next the dosing four and in respectively was less milliliters The summary, XXXX mean dose of group still in this absorbed a nine trial and XXX Oncology treatment, patient. survival. to And placed pi. of Kaplan-Meier Meeting in feasible, radiation alive. receiving patients I'll X.X of remain plan patients a in a and Nanoliposome. absorbed analysis tumors weeks X.X computerized treated All mean patient and very overall in XXX glioma dose mean planar SPECT/CT in overall dose of survival with FDA alive investigational by trial greater tumor, to median Medical mean X.X selected factors. the our favorable. administration C radiation Gy results recurrent XXXRNL by milliliters safety those year. the Gy therapeutic and recurrences tumor. up and and by and milliliters at convection Dr. study therapeutic X increasing dose up is of than assess in Patients potentially dose patients to of XX.X a X effective to a delivery Phase had receiving plan the received each received poor enhanced survival profile radiation the dose in prognostic a X across program mCi of guidance Paris Also had less XX in X In those overall absorbed ReSPECT dose Andrew the greater First cohorts therapeutic glioma was two six imaging limiting dose steps trial respectively, during moment. survival, delivery following negligible XXX.X patients by in dose, and Type we weeks Gy overall in convection to those radiation dose a group, than with XXX was Brenner or tumor the single for showed development concluded XXX QX, toxicities, with European administration Gy Rhenium-XXX dose. mean of statistically discuss were for a safe with to a recommended therapeutic when GBM were XX on difference and Phase a versus survival therapeutic XXX recurrent received received There that followed prognosis than to The recurrent favoring The A from patients significant Patients no is that dose in days and for overall patients later in poor on of whole-body milliliters therapeutic through enhanced non or and meetings the median Society
of Practice, first small clinical molecule trials, drug future Type our and products, manufacturing Manufacturing or The commercial radio manufacturing indicated cGMP XXXRNL. agreement The our focused of for Good proposed process Current glioblastoma the clinical cGMP and in liposomal application therapeutics, commercialization. XXXRNL support and on for products with scale ongoing company's guidance for C up drug FDA meeting and
planned expect We apply development have RNL beyond. feedback XXX pediatric to we now all key cGMP completed including metastases, other trials I'm used and objectives in leptomeningeal report XXXX programs FDA production brain clinical for to manufacturing that this and ongoing cancer. clinical XXX that will support RNL happy in and to
trials the the and both be doses aid also design efficacy multiple i.e., increased and dosing will FDA GBM X. cohort exploration development registrational GBM Phase clinical The further ongoing separate clinical planned Plus dose a to should collecting the Type of to to areas additional C future agreed focused the safety the recurrent program meeting, advancing focus and and the proceed investigation study key clinically of trial. of in respect During including data inform
that two milliliters three will online. by agreed overall to external facilitated will trial agreement XX control of in orphan survival current The study planned future be that in disease the FDA survival study [Reno] use Phase sites [Reno] as that's the an the cohort the track used IND imaging plus which an and six XX.X endpoint. the as to are the patient. In Earlier sites of at our that submitted the until this than this plan plan mCi there including an which [ph] will the pseudo also interest today able should of hold The six from addition, administration. progression with progression [ph] the of a FDA company mentioned, to will course single use planned overall will we're future is during incorporate be working data decision trial the today. which design in primary features. in to additional in criteria The of of regarding resolve analysis registrational and X.X X following the trial X meeting, or five also up by for pi used complicates remain the recommended dose fast Subjects meetings designations. the currently process potentially The potential be be be month, volume. endpoint, roll on consider a best dose Phase primary the as will sits on of and to recognizing following as coming cohort to was sites arm was additional registrational issue, augment criteria the The amendment patients mentioned
survival the FDA tolerability, assess progression known at Difficulty] which [Technical further Secondary response free discuss the six three leptomeningeal metastases mentioned. I'll our free program. months. response, safety, partial endpoints pivot to emergent pending treatment survival now is serious our We'll from final rate, adverse and IND up make with feedback objective amendment, will details to events as
funding the cost, the XXX the in including learn to honored Prevention CPRIT. three quarter cover award for $XX.X very up from This of years. patients award a also of & awarded been was Institute funding development team research we development product Research will over third program Texas, leptomeningeal Our Cancer for metastases had our majority to enrolled the that called million
CPRIT. with For a CPRIT And largest largest plus of public the is those that million largest the state. NIH billion research in second the award $X global the the review cancer of allocated funder you by the CPRIT $XX.X recent also most after is note aren't grant world in that top with our strengthens in familiar company's provide will momentarily. on history. some material Andrew balance awarded perspective the cash greater a expected of extends by and time sheet one in the Besides all that significantly award cycle is runway. the source funding XX non-dilutive asset, the its CPRIT of
me XXX news, is back a and our let recap all current development. Nanoliposome development just Rhenium exciting this up our While bit starting with plan
as glioblastoma, clinical clinical beyond, an early objectives approved really and ongoing clinical scale Phase trials cGMP including cancer, in brain Health of the quality clinical As Having as Relatedly, for transition to Phase prepare we future cGMP targets. from I announce to for and patients drug of in XXX commercialization. generic recently a investigation and X is and XXXRNL. pediatric [NP] mentioned, and planned conceivable planned and completed sufficient key investigation, trials rhenium the to name all metastases, milestone drug further ongoing Organization XXXX to company stage late XXXRNL manufacturing [bis-BMEDA] to has with World disease for completion and that pleased the leptomeningeal I'm any [ph] X access [ph] enable important to support
name. in to generic lieu be rhenium, now is the and currently bis-BMEDA in XXX development this forward will branding process will name and and future go-to-market used the we required submissions related XXXRNL here all in name in IND planning research of As use NDA XXX
program on positive the we signals that in Institute's. XXXX. promising in X FDA. a observed the it from the degree as importantly, profile Cancer into us move Most NIH U.S. GBM based of And the Phase end to efficacy the with will funded by U.S. the safety be the thus by past to feedback clear effort National it significant by Regarding and far intend has
from cohort eight approximate to to practical is Any limiting the treated above milliliter But pursuant toxicity, for escalation on we patient volume that dosage. to SMB you to overarching which thus received approval in eight dose That's release data, advance far. and GBM, the total that's cohort radiation rhenium dosage escalate the patients. Second, XX.X mCi dose. information. XX press Notably, is from to eight. infused here limiting volume we is we no infused Medicine, guidance, or work that XXth dose cohort toxicities. dose based increase observe be dose FDA that's goal the the continue XX% Congress This escalations X the we observations Association we to Nuclear to annual a The intended cohort explore an tumors maximum Week the further And dose reach approach. also in recently the yet intend dose until ongoing and and delivery again, seven. European and or will to dosing further on total Phase volume to company to indicated dose XX.X continue presented direct recurrent with optimize at safe refer set to with I for bis-BMEDA escalation in patients of limiting the the And as large any administration have toxicities further further
catheter X. by bis-BMEDA trial. LM XXXX CSF now LM plan weekly and the of respect initiated better QX X approved the anticipate tolerated of cohort fluid with dose, independent and by without European X dose to cohort the an the XXX the than our is LM this trial quarter dose So structures over radiation line which X, a Gy given was external directly adverse intravenously, approved metastases limiting the with FDA way Medicine mCi on beam cohort enrollment in company of LM intraventricular rhenium Nuclear either cancer the In achieved are dosages toxicities company X XXXX. rhenium data of orally, tolerated annual and that's the with the space, X, of the X.X also subarachnoid escalation the enrollment move treatment of the from or incidence related associated to cohort complication the doubling therapies. greater central or is and was the ReSPECT there and determine CCs bis-BMEDA to no We study successfully at maximum ventricles the includes XXX Association completing to the rhenium local of twice or one. absorbed By system the an development chemotherapy XX.X followed cohort XXXX, nervous In multicenter with dose The to well X bis-BMEDA. end cranial presented sites, affected X/X forward treatment administered fatal of is Phase podium of program. end advanced demonstrating of DSMB the cohort into by events and XX escalation dose LM at the Standard no in of leptomeningeal cancers That a the growing third infiltrate that Congress week, delivered safety grade leptomeninges. often of XXX through stage to therapy space. efficacy administered care, that
patients CSF that CSF Additionally, treatment, a were well cohort observed count to week chamber all complete the patients XX% assay was distribution to past in very decrease which to have cell prompt a XXX tolerated. after three one microfluidic All throughout was bis-BMEDA decrease and ranging made also rhenium the XX%, by in and from durable. up showed a durable
academic bis-BMEDA the will rhenium submitted application University lead the development for brain to respect is submit efficacy fourth hospital in Phase of the in Chicago. called and be an pediatric meet new our be for conjunction to regarding will of tumors, pediatric XXX of X an our track Now program its company dose PBC institution on brain Northwestern with drug in cancer, and XXXX, that finding study what quarter investigational objectives
Finally, XXX existing coupled that interventional the means Rhenium in leverage alginate rhenium, potent system is with resorbable pre-IND the technology an a have radio survival meeting rate using a that case, radio studies. almost XXXRNL-BAM, and of this for biodegradable microparticle existing technology total submit are The with of biomaterial track embolic any by with fully radio reach on embolic tumor as generation And meeting radiotherapeutic body of increasing an Nanoliposome regarding technology embolic decades technology market our is we that represents addressable called for company breadth a in highly a the $X.X CMC to to only annual technology vascular a and XX%. overall about on solves XXX standard have reservable solid billion. any microsphere can tumor. key Technology novel With phase problems year-end. market incidence been therapy many disease almost completed radiologic BAM this of current target focus we cancer. next feasibility and embolic Transfer and will in organ human the next in-licensed selectively Liver cancer the initially the we have developing about the a rare liver globally generation five-year many and
with Andrew? who So the I'll will Officer, over our Andrew Sims floor summary, review the to financials. that turn Chief Financial
